# US 2020/0400657 A1 · Antibody screening methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400657 A1
- Document ID: US20200400657A1
- Status: Published application
- Kind: A1
- Application number: 16/862,851
- Filed: 2020-04-30
- Published: 2020-12-24
- Earliest claimed: 2011-03-15
- Assignees: X-Body, Inc.
- Applicants: X-Body, Inc.
- Inventors: Yan CHEN; Tod M. WOOLF; Richard W. WAGNER
- Web page: https://patentgrep.com/patent/US20200400657A1

## CPC

- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C07K 16/005: {constructed by phage libraries}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/6854: {Immunoglobulins}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are methods and compositions for the production of novel antibodies that bind specifically to a target antigen. These methods and compositions are particularly useful for producing antibodies having the antigen binding specificity of a reference antibody but with improved properties (e.g., binding affinity, immunogenicity, and thermodynamic stability) relative to the reference antibody.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method for selecting a bispecific, stable VH/VL pair, the method comprising:
(a) providing an unpaired VH domain that binds specifically to a first antigen;
(b) contacting the unpaired VH domain with a library of unpaired VL domains such that a library of VH/VL pairs is formed;
(c) contacting the library of VH/VL pairs with a second antigen;
(d) selecting from the library of VH/VL pairs at least one VH/VL pair that binds specifically to the second antigen;
(e) contacting the VH/VL pair(s) selected in step (d) with the first antigen; and
(f) selecting at least one VH/VL pair that binds specifically to the first antigen, thereby selecting a bispecific, stable VH/VL pair.

### Claim 16 (depends on 15)

The method of claim 15, further comprising the step of introducing additional amino acid sequence diversity into the library of unpaired VL domains of step (b).

### Claim 17 (depends on 16)

The method of claim 16, wherein the additional amino acid sequence diversity is introduced by random mutagenesis.

### Claim 18 (depends on 15)

The method of claim 15, wherein the library of unpaired VL domains of step (b) comprises human VL domains.

### Claim 19 (depends on 15)

The method of claim 15, wherein the library of unpaired VL domains is a nucleic acid display library.

### Claim 20 (depends on 15)

The method of claim 15, wherein the unpaired VH domain of step (a) is produced by
(a) providing a library of chimeric, unpaired VH domains wherein diversity lies in the FR1-FR3 regions, and wherein each member of the library comprises the CDR3 region sequence from the VH domain of a reference antibody that binds specifically to the first antigen;
(b) contacting the library with the first antigen; and
(c) selecting from the library at least one chimeric, unpaired VH domain that binds specifically to the first antigen, thereby producing an unpaired VH domain that binds specifically to the first antigen.

### Claim 21 (depends on 15)

The method of claim 15, further comprising the step of expressing the selected VH/VL pair in a cell.

### Claim 22 (depends on 15)

The method of claim 15, wherein the library is generated using at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 70, 71, 72, 73, 74, 75, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, and 102.

### Claim 23

An oligonucleotide having a sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 70, 71, 72, 73, 74, 75, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, and 102.

### Claim 24 (depends on 15)

The method of claim 15, wherein the library of VH/VL pairs is a nucleic acid display library.

### Claim 25 (depends on 15)

The method of claim 15, further comprising the step of expressing an antibody comprising the VH/VL pair in a cell.
